Digital Therapeutics for Chemo Nausea Market 2034

Report Description

This report is updated with the latest market data and insights as of June 2026. Base year: 2025  |  Forecast period: 2026-2034

Digital Therapeutics Chemotherapy-Induced Nausea Market Outlook

According to our latest research, the global market size for Digital Therapeutics for Chemotherapy-Induced Nausea was valued at USD 1.34 billion in 2025, with a robust CAGR of 17.8% projected for the forecast period. This dynamic growth is anticipated to propel the market to approximately USD 6.97 billion by 2034. The rapid expansion of this market is primarily driven by the increasing incidence of cancer worldwide, the growing adoption of digital health solutions in oncology care, and the urgent need for effective, non-pharmacological interventions to manage chemotherapy-induced nausea and vomiting (CINV). As per our latest research, advances in digital therapeutics, coupled with a decisive shift towards patient-centric care, are further fueling market momentum across all major geographies. The broader landscape of oncology-focused digital therapeutics is expanding rapidly, creating a strong tailwind for CINV-specific solutions.

Get Free Sample Report

The surge in cancer cases globally is one of the most significant growth factors for the Digital Therapeutics for Chemotherapy-Induced Nausea market. With over 20 million new cancer diagnoses expected annually in 2025, the demand for effective supportive care solutions has never been higher. Chemotherapy, while lifesaving, often brings distressing side effects such as nausea and vomiting, which can severely impact patient quality of life and treatment adherence. Digital therapeutics (DTx) offer evidence-based, software-driven interventions that can be tailored to individual patient needs, providing real-time symptom management, education, and behavioral support. These solutions are increasingly being integrated into oncology care pathways, as they not only improve patient outcomes but also reduce the burden on healthcare systems by minimizing emergency visits and hospitalizations due to uncontrolled CINV.

Another critical driver of market growth is the technological advancement and integration of artificial intelligence (AI), machine learning, and mobile health platforms within digital therapeutics. The proliferation of smartphones and wearable devices has made it possible to deliver personalized interventions and monitor patient symptoms remotely. These innovations allow for continuous patient engagement, real-time feedback, and adaptive therapy adjustments, making digital therapeutics highly effective for managing chemotherapy-induced nausea. Moreover, regulatory support and increasing reimbursement coverage for digital health solutions are encouraging healthcare providers to adopt these technologies at scale. The growing body of clinical evidence supporting the efficacy of digital therapeutics in reducing CINV is also bolstering confidence among oncologists and patients alike. Parallel advancements in managing gastrointestinal conditions through DTx, such as those explored in the digital therapeutics functional dyspepsia segment, are informing best practices that benefit CINV solution developers as well.

The evolving landscape of healthcare delivery, with an increasing emphasis on home-based care and telemedicine, is further accelerating the adoption of digital therapeutics for chemotherapy-induced nausea. The COVID-19 pandemic underscored the importance of remote patient monitoring and digital health interventions, leading to a lasting paradigm shift in how supportive cancer care is delivered. Patients and caregivers are now more receptive to using digital platforms for symptom management, education, and communication with healthcare teams. This shift is particularly relevant for rural and underserved populations, where access to specialized oncology care may be limited. As healthcare systems worldwide continue to embrace digital transformation through 2025 and beyond, the market for digital therapeutics targeting CINV is expected to experience sustained and accelerating growth.

From a regional perspective, North America currently dominates the Digital Therapeutics for Chemotherapy-Induced Nausea market, accounting for over 41.2% of the global market share in 2025. This leadership is attributed to the region's advanced healthcare infrastructure, high prevalence of cancer, and strong presence of digital health innovators. Europe follows closely, driven by supportive regulatory frameworks and increasing investment in digital health. The Asia Pacific region is emerging as a lucrative market, fueled by rising cancer incidence, expanding digital connectivity, and growing awareness of digital therapeutics. Latin America and the Middle East and Africa, though at earlier stages of adoption, are expected to witness accelerated growth as healthcare systems modernize and digital health initiatives gain significant traction.

Product Type Analysis

The Product Type segment in the Digital Therapeutics for Chemotherapy-Induced Nausea market is categorized into software applications, devices, and platforms. Software applications represent the largest share of this segment at approximately 54.5%, reflecting the widespread adoption of mobile health apps and web-based solutions for symptom management. These applications are designed to deliver cognitive behavioral therapy (CBT), provide educational content, track symptoms, and offer real-time guidance to patients undergoing chemotherapy. The ease of integration with smartphones and tablets, coupled with user-friendly interfaces, has made software applications the preferred choice for both patients and healthcare providers. Continuous updates, cloud-based data storage, and interoperability with electronic health records (EHRs) further enhance their utility in clinical practice.

Get Free Sample Report

Devices, including wearable sensors and connected health monitors, account for approximately 24.8% of the market and are gaining traction as adjuncts to software-based therapeutics. These devices enable continuous physiological monitoring, such as tracking heart rate, skin temperature, and other biomarkers that may signal the onset of nausea or vomiting. By providing objective data, devices support more accurate symptom assessment and allow for timely intervention, thus improving patient outcomes. The integration of devices with digital therapeutics platforms also supports remote monitoring by clinicians, ensuring that patients receive proactive care even outside traditional healthcare settings. As device technology becomes more sophisticated and affordable, adoption is expected to rise steadily, particularly in high-risk patient populations requiring close surveillance during active chemotherapy cycles.

Platforms represent a holistic approach to digital therapeutics, accounting for roughly 20.7% of the market and offering comprehensive solutions that combine software applications, device integration, data analytics, and communication tools within a unified ecosystem. These platforms are designed to support the entire patient journey, from initial diagnosis through treatment and survivorship. They facilitate seamless information sharing among patients, caregivers, and healthcare teams, enabling coordinated care and personalized interventions. Platforms also support population health management by aggregating data across patient cohorts, providing valuable insights for clinical decision-making and research. The scalability and flexibility of digital therapeutics platforms make them particularly attractive for large healthcare organizations and cancer treatment centers seeking to standardize supportive care protocols across their networks. Notably, insights from adjacent digital therapeutic categories, including vestibular migraine management platforms, are influencing platform architecture decisions relevant to nausea-centric applications.

The competitive landscape within the product type segment is characterized by rapid innovation and frequent product launches. Leading companies are investing in research and development to enhance the functionality and efficacy of their digital therapeutics offerings. Strategic partnerships with oncology centers, technology firms, and academic institutions are common, as companies seek to expand their reach and validate their solutions through rigorous clinical trials. Regulatory approvals, such as FDA clearance for specific software applications and devices, are also critical factors influencing market dynamics. As the evidence base for digital therapeutics grows, product differentiation will increasingly hinge on clinical outcomes, user experience, and integration capabilities with existing hospital and clinic workflows.

Looking ahead to the 2026-2034 forecast period, the product type segment is poised for significant evolution as emerging technologies such as virtual reality (VR), augmented reality (AR), and voice-enabled interfaces are incorporated into digital therapeutics for chemotherapy-induced nausea. These innovations have the potential to enhance patient engagement, improve adherence, and deliver more immersive therapeutic experiences. The convergence of digital therapeutics with precision medicine, leveraging genomics and personalized risk profiles, is also expected to drive the next wave of product development. As the market matures, interoperability and data security will remain key priorities, ensuring that digital therapeutics solutions are both clinically effective and trustworthy for patients and providers alike.

Report Scope

Therapy Area Analysis

Within the Therapy Area segment, oncology remains the primary focus of digital therapeutics for chemotherapy-induced nausea, given the high global prevalence of cancer and the widespread use of chemotherapy as a standard treatment modality. Digital therapeutics in oncology are designed to address the unique challenges faced by cancer patients, including the management of complex symptom clusters, psychological distress, and treatment-related side effects. These solutions leverage evidence-based interventions such as cognitive behavioral therapy and mindfulness techniques to help patients cope with nausea, anxiety, and related symptoms. The integration of patient-reported outcomes (PROs) and real-time symptom tracking enables personalized care and timely adjustments to treatment plans, ultimately improving patient quality of life and adherence to therapy through 2025 and beyond.

Supportive care, as a distinct therapy area, is gaining prominence in the digital therapeutics market. This sub-segment encompasses interventions aimed at alleviating the side effects of cancer treatment, enhancing patient comfort, and supporting overall well-being. Digital therapeutics for supportive care extend beyond nausea management to address issues such as pain, fatigue, sleep disturbances, and emotional health. By providing comprehensive support, these solutions help patients maintain their functional status and reduce the risk of treatment interruptions. The growing recognition of supportive care as an integral component of oncology care is driving sustained investment in digital therapeutics tailored to the unique needs of this patient population. The methodologies being refined in gastrointestinal symptom management via digital therapeutics are also informing supportive care protocol development for CINV.

Other therapy areas, including palliative care and chronic disease management, are emerging as important segments within the digital therapeutics market for chemotherapy-induced nausea. Palliative care focuses on improving the quality of life for patients with advanced cancer, offering symptom relief and psychosocial support. Digital therapeutics in this context provide tools for symptom monitoring, advance care planning, and communication with multidisciplinary care teams. Chronic disease management, while not exclusively related to chemotherapy-induced nausea, shares common challenges in symptom control and patient engagement, making digital therapeutics solutions transferable across different clinical contexts. The cross-pollination of best practices from oncology and supportive care is expected to drive innovation and expand the market reach of digital therapeutics well into the 2026-2034 forecast period.

The therapy area segment is characterized by a strong emphasis on clinical validation and evidence generation. Regulatory agencies and payers increasingly require robust data demonstrating the safety, efficacy, and cost-effectiveness of digital therapeutics in specific therapy areas. As a result, companies are investing in randomized controlled trials, real-world evidence studies, and health economic analyses to support product claims and secure market access. Collaboration with leading cancer centers and academic institutions is common, as these partnerships facilitate access to patient populations and clinical expertise necessary for rigorous validation. The growing body of evidence supporting digital therapeutics in oncology and supportive care is expected to drive wider adoption and integration into standard care pathways globally.

Looking forward through 2034, the therapy area segment is likely to see continued diversification as digital therapeutics are developed for additional indications and patient populations. The integration of digital therapeutics with precision oncology, leveraging biomarkers and genetic data, holds strong promise for delivering highly personalized interventions. Advances in artificial intelligence and machine learning will further enhance the ability of digital therapeutics to predict symptom trajectories and optimize therapy delivery in real time. As the market evolves, the ability to demonstrate meaningful clinical outcomes and tangible value for patients, providers, and payers will be the defining criterion for success in the therapy area segment.

End-User Analysis

The End-User segment for Digital Therapeutics for Chemotherapy-Induced Nausea is broadly categorized into hospitals, cancer treatment centers, homecare settings, and others. Hospitals represent a significant share of the market, as they are the primary sites for cancer diagnosis, treatment initiation, and acute care management. Digital therapeutics are increasingly being integrated into hospital-based oncology programs to support symptom management, patient education, and care coordination. The ability to monitor patients remotely and intervene early in the event of severe nausea or vomiting helps reduce hospital admissions and improve resource allocation. Hospitals also play a critical role in validating and standardizing digital therapeutics solutions, ensuring that they meet rigorous clinical and regulatory requirements before broader deployment.

Cancer treatment centers, including specialized oncology clinics and comprehensive cancer centers, are at the forefront of adopting digital therapeutics for chemotherapy-induced nausea. These centers often serve as innovation hubs, piloting new technologies and conducting clinical trials to assess their impact on patient outcomes. Digital therapeutics are used to support multidisciplinary care teams, facilitate communication among providers, and engage patients in active self-management. The focus on personalized medicine and value-based care in cancer treatment centers aligns well with the core capabilities of digital therapeutics, driving their adoption and deep integration into care pathways. Partnerships between digital therapeutics companies and leading cancer centers are common, enabling rapid deployment and iterative product improvement based on real-world clinical feedback.

Homecare settings are emerging as a critical and fast-growing end-user segment, reflecting the dominant trend towards outpatient and home-based cancer care in 2025. Digital therapeutics enable patients to manage chemotherapy-induced nausea in the comfort of their own homes, reducing the need for frequent hospital visits and improving overall quality of life. Remote monitoring, symptom tracking, and virtual coaching are key features of digital therapeutics solutions designed for homecare. These tools empower patients and caregivers to take an active role in symptom management, while providing clinicians with real-time data to guide treatment decisions. The shift towards home-based care was significantly accelerated by the COVID-19 pandemic and has become firmly embedded in oncology care delivery models moving into 2025 and the forecast period.

Other end-users, including primary care providers, rehabilitation centers, and patient advocacy organizations, play a supportive and growing role in the adoption of digital therapeutics for chemotherapy-induced nausea. Primary care providers often serve as the first point of contact for patients experiencing side effects, and digital therapeutics can facilitate timely referral and coordination with oncology specialists. Rehabilitation centers use digital therapeutics to support recovery and symptom management in cancer survivors navigating the post-treatment phase. Patient advocacy organizations are increasingly involved in promoting awareness, education, and equitable access to digital therapeutics, advocating for patient-centered care and improved quality of life across diverse populations.

The end-user segment is characterized by diverse needs and preferences, requiring digital therapeutics companies to tailor their solutions carefully to different care settings and patient populations. Successful adoption depends on factors such as ease of use, integration with existing clinical workflows, data security, and demonstrated clinical value. Training and ongoing support for healthcare providers, patients, and caregivers are essential to ensure effective implementation and sustained engagement over the treatment lifecycle. As the market matures through 2034, collaboration among all stakeholders will be critical to overcoming remaining barriers and maximizing the positive impact of digital therapeutics across the full cancer care continuum.

Distribution Channel Analysis

The Distribution Channel segment in the Digital Therapeutics for Chemotherapy-Induced Nausea market includes direct sales, online platforms, and others. Direct sales channels remain a dominant mode of distribution, particularly for hospitals, cancer treatment centers, and large healthcare organizations. Through direct sales, digital therapeutics companies can establish close relationships with key clinical and administrative decision-makers, provide customized solutions, and offer ongoing technical and implementation support. Direct sales also facilitate integration with existing healthcare IT systems, ensuring seamless deployment and interoperability. The ability to demonstrate clear clinical value and cost-effectiveness is critical in this channel, as purchasing decisions are often made by multidisciplinary committees and subject to rigorous evaluation processes.

Online platforms are rapidly gaining prominence as a distribution channel for digital therapeutics, reflecting broader trends in digital health and the consumerization of healthcare services. These platforms enable patients, caregivers, and healthcare providers to access digital therapeutics solutions directly, often through app stores, dedicated websites, or integrated telehealth portals. The convenience, accessibility, and scalability of online platforms make them particularly attractive for homecare settings and individual users managing CINV outside of hospital environments. Online platforms also support rapid dissemination of product updates, integration with wearable devices, and real-time data analytics capabilities. As regulatory frameworks continue to evolve to support the direct-to-consumer model, online platforms are expected to play an increasingly important and expanding role in driving market adoption through 2034.

Other distribution channels, including partnerships with pharmaceutical companies, medical device manufacturers, and insurance providers, are emerging as strategic and high-value avenues for market expansion. Pharmaceutical companies are increasingly interested in digital therapeutics as complementary solutions that can enhance the overall efficacy and safety profile of chemotherapy regimens. Co-marketing and co-development agreements enable digital therapeutics companies to leverage the established distribution networks and deep clinical expertise of major industry players. Insurance providers are also exploring digital therapeutics as a cost-reduction tool, offering reimbursement and coverage for eligible solutions that demonstrably reduce hospitalizations and emergency interventions related to uncontrolled CINV. These collaborative partnerships are instrumental in driving meaningful market penetration and ensuring long-term commercial sustainability.

The distribution channel segment is characterized by a dynamic and rapidly evolving landscape, with companies experimenting with hybrid models to reach diverse customer segments across geographies. The choice of distribution channel depends on factors such as target end-user type, applicable regulatory requirements, and market maturity in each region. Successful distribution strategies require a deep and nuanced understanding of customer needs, robust technical infrastructure, and effective marketing and clinical education initiatives. As competition intensifies across the forecast period, differentiation based on user experience, clinical outcome data, and value-added services will be key to achieving sustainable success in this segment.

Looking ahead through 2034, the distribution channel segment is expected to continue evolving as new technologies and innovative business models emerge. The integration of digital therapeutics with telemedicine platforms, electronic health records, and advanced remote monitoring solutions will create new opportunities for seamless care delivery and data-driven clinical decision-making. Regulatory harmonization across major markets and increased reimbursement coverage will further support broad market growth, enabling significantly more patients worldwide to benefit from digital therapeutics for chemotherapy-induced nausea.

Opportunities and Threats

The Digital Therapeutics for Chemotherapy-Induced Nausea market presents significant opportunities for growth and innovation, particularly as healthcare systems worldwide prioritize patient-centered, value-based care in 2025 and beyond. One of the most promising opportunities lies in the integration of digital therapeutics with precision oncology, leveraging genomic data and personalized risk profiles to deliver highly tailored interventions at scale. Advances in artificial intelligence and machine learning are enabling the development of predictive algorithms that can identify patients at highest risk of severe nausea and optimize therapy delivery accordingly. The expansion of telehealth and remote monitoring capabilities is also creating new avenues for reaching underserved and rural populations and delivering high-quality care in home-based settings. As regulatory agencies increasingly recognize the clinical value of digital therapeutics, opportunities for reimbursement and streamlined market access are expanding, further driving adoption across all end-user segments.

Another major opportunity is the potential for digital therapeutics to meaningfully improve patient engagement and adherence, leading to better clinical outcomes and substantially reduced healthcare costs over the long term. By providing real-time symptom tracking, personalized feedback, and virtual coaching, digital therapeutics empower patients to take an active and informed role in their own care. This can lead to earlier clinical intervention, fewer unplanned emergency visits, and improved quality of life for patients undergoing chemotherapy. The growing body of clinical evidence supporting the efficacy of digital therapeutics in managing CINV is also opening important doors for strategic partnerships with pharmaceutical companies, insurance providers, and integrated health systems. Collectively, these collaborations can accelerate market penetration, support rigorous product validation, and ensure commercial sustainability across the 2026-2034 forecast horizon.

Despite these compelling opportunities, the market faces several restraining factors that could impede growth trajectories. One of the primary challenges is the ongoing need for robust and diverse clinical evidence to support the safety, efficacy, and cost-effectiveness of digital therapeutics across heterogeneous patient populations. Regulatory requirements vary significantly by region, and navigating complex and often lengthy approval processes can be time-consuming and costly for innovative companies. Data privacy and cybersecurity concerns are also significant barriers, particularly as digital therapeutics solutions collect, transmit, and store sensitive patient health information at scale. Ensuring genuine interoperability with existing healthcare IT infrastructure and securing durable reimbursement commitments from payers remain additional structural hurdles. Overcoming these challenges will require sustained investment in rigorous research, deep collaboration among industry stakeholders, and an unwavering commitment to quality, transparency, and patient safety.

Regional Outlook

Regionally, North America leads the Digital Therapeutics for Chemotherapy-Induced Nausea market, with a market value of approximately USD 552 million in 2025, accounting for over 41.2% of the global market. This dominance is attributed to the region's advanced healthcare infrastructure, high prevalence of cancer, and a uniquely strong ecosystem of digital health innovators and investors. The United States, in particular, has been at the forefront of digital therapeutics adoption, supported by favorable regulatory frameworks, progressively expanding reimbursement policies, and a deeply embedded culture of healthcare innovation. Leading academic medical centers and comprehensive cancer institutes in North America have played a pivotal role in validating and deploying digital therapeutics solutions, driving widespread clinical adoption across the region throughout the historical period from 2019 to 2024 and into the 2025 base year.

Get Free Sample Report

Europe is the second-largest market, valued at approximately USD 335 million in 2025, driven by supportive regulatory frameworks, increasing public and private investment in digital health, and a growing emphasis on patient-centered and value-based oncology care. Countries such as Germany, the United Kingdom, and France have implemented comprehensive digital health strategies that actively promote the integration of digital therapeutics into oncology care pathways. The region's established focus on evidence-based medicine and rigorous health technology assessment has fostered a culture of innovation and quality assurance. Europe is expected to maintain a steady CAGR of approximately 17.2% through 2034, supported by ongoing investment in translational research, expanding public-private partnerships, and continuously improving digital health infrastructure across member states.

The Asia Pacific region is emerging as a high-growth market, valued at approximately USD 265 million in 2025 and projected to expand at a CAGR of 19.4% through 2034, making it the fastest-growing regional market globally. The rising incidence of cancer, rapidly expanding digital connectivity, and growing awareness of the clinical and economic benefits of digital therapeutics are key drivers of market growth across the region. Countries such as China, Japan, South Korea, and India are making substantial investments in digital health initiatives and expanding access to specialized cancer care services. The accelerating shift towards home-based care and telemedicine is particularly relevant in Asia Pacific, where geographic barriers frequently limit access to specialized oncology centers. Latin America and the Middle East and Africa, though smaller in current market size at approximately 8.2% and 5.8% of the global market respectively, are expected to witness significantly accelerated growth through 2034 as healthcare systems modernize, cancer awareness improves, and targeted digital health initiatives gain meaningful momentum.

Competitor Outlook

The Digital Therapeutics for Chemotherapy-Induced Nausea market in 2025 is characterized by a highly competitive and dynamic landscape, with a diverse mix of established healthcare technology companies, focused digital health innovators, and pharmaceutical firms pursuing market share. The competitive environment is shaped by rapid technological innovation, frequent product launches, and continuously evolving regulatory requirements. Companies are differentiating themselves through the depth of clinical validation, quality of user experience, and sophistication of integration capabilities, as well as through high-value partnerships with healthcare providers, leading academic institutions, and commercial payers. The ability to demonstrate meaningful clinical outcomes and quantifiable cost savings is increasingly important, as healthcare systems globally accelerate their transition towards value-based care models throughout the forecast period.

Strategic collaborations and mergers and acquisitions are common in this market, as companies seek to expand their product portfolios, access new geographic markets, and accelerate the pace of innovation. Leading digital therapeutics firms are actively partnering with pharmaceutical companies to co-develop and co-market integrated solutions that complement existing chemotherapy regimens. These partnerships enable companies to leverage the clinical expertise, established distribution networks, and regulatory experience of major industry players. Investment in research and development remains a key strategic focus, with companies conducting both prospective clinical trials and real-world evidence studies to support product claims and secure necessary regulatory approvals in multiple markets simultaneously. The competitive landscape is further invigorated by the entry of well-resourced technology companies and consumer health platforms that bring formidable capabilities in digital platform development, advanced data analytics, and large-scale user engagement.

Regulatory approval and reimbursement pathways are critical and differentiating factors shaping competitive dynamics in the digital therapeutics market. Companies that achieve early regulatory clearance and successfully secure reimbursement coverage from commercial and government payers are well-positioned to capture meaningful market share and drive rapid adoption across target end-user segments. The ability to integrate seamlessly with electronic health records, established telemedicine platforms, and remote patient monitoring solutions is also a key differentiator, as healthcare providers increasingly demand interoperable and workflow-compatible solutions. Data privacy and security remain paramount competitive considerations, with companies investing heavily in enterprise-grade cybersecurity infrastructure and maintaining strict compliance with international standards including HIPAA in North America and GDPR across Europe.

Major players in the Digital Therapeutics for Chemotherapy-Induced Nausea market include Voluntis (Aptar Digital Health), Biofourmis, Sidekick Health, Mymee, and Mahana Therapeutics. Voluntis, now integrated within Aptar Digital Health, has developed clinically validated digital therapeutics solutions for oncology and supportive care, with a strong emphasis on integration with healthcare systems and robust real-world evidence generation. Biofourmis leverages advanced analytics and wearable sensor technologies to deliver predictive and adaptive digital therapeutics that enable proactive clinical management of CINV and related symptoms. Sidekick Health offers a gamified and highly personalized digital therapeutics platform specifically designed to maximize patient engagement and long-term adherence throughout chemotherapy treatment cycles. Mymee provides patient-centric digital therapeutics solutions that are carefully tailored to individual symptom profiles and unique treatment response patterns. Mahana Therapeutics focuses on rigorously validated cognitive behavioral therapy-based digital interventions, with a growing presence in oncology supportive care applications.

Other notable and actively competing companies include Click Therapeutics, Twill, Xealth, Kaia Health, Amalgam Rx, WellDoc, Omada Health, Big Health, MindMaze, and Ginger (Headspace Health). Click Therapeutics is recognized for its prescription digital therapeutics pipeline and commitment to FDA-cleared, evidence-based software interventions. Twill provides comprehensive digital health platforms with strong mental health and symptom management capabilities applicable to oncology supportive care. Xealth specializes in clinical digital health integration, connecting digital therapeutics directly within hospital EHR workflows to support prescribing and monitoring by oncology teams. As the market continues to evolve and scale through the 2026-2034 forecast period, new entrants and technology innovators are expected to drive further competitive intensity and disruptive innovation, ultimately delivering compounding benefits for patients and healthcare systems worldwide.

Key Players

• Voluntis (Aptar Digital Health)
• Biofourmis
• Sidekick Health
• Mymee
• Mahana Therapeutics
• Click Therapeutics
• Twill
• Xealth
• Kaia Health
• Amalgam Rx
• WellDoc
• Omada Health
• Big Health
• MindMaze
• Ginger (Headspace Health)